Skip to Content

Celldex Therapeutics Announces Poster Presentations of Lead Product Candidates at ASCO Annual Meeting

PHILLIPSBURG, N.J., May 30, 2007 /PRNewswire/ -- Celldex Therapeutics announced today that clinical data from studies with its two lead product candidates, CDX-110 and CDX-1307, will be presented during poster sessions at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). The ASCO meeting is being held at McCormick Place in Chicago, IL from Friday, June 1 through Tuesday, June 5.

The CDX-110 poster "Temozolomide as a vaccine adjuvant in GBM" will be displayed during the "Central Nervous System Tumors" poster discussion session on Sunday, June 3, between 8:00 a.m. and 12:00 p.m.

The CDX-1307 poster entitled "Antigen presenting cell (APC)-targeted hCG Beta vaccine for cancer therapy" will be on display during the "Developmental Therapeutics: Immunotherapy" poster discussion session on Sunday, June 3 between 2:00 p.m. and 6:00 p.m.

Both presentations will be on display in location S 102a at their respective times.

About CDX-110

CDX-110 is an investigational immunotherapy that targets the tumor specific molecule EGFRvIII, a functional variant of the epidermal growth factor receptor (EGFR), which is a protein that has been well validated as a target for cancer therapy. This particular variant, EGFRvIII, was discovered in a collaborative effort between Dr. Bert Vogelstein and Dr Albert Wong at Johns Hopkins University and Dr. Darell Bigner at Duke University. Unlike EGFR, EGFRvIII is not present in normal tissues, suggesting this target will enable the development of a tumor-specific therapy for cancer patients. Furthermore, EGFRvIII is a transforming oncogene that can directly contribute to cancer cell growth. While originally discovered in Glioblastoma Multiforme (GBM), the most common and aggressive form of brain cancer, the expression of EGFRvIII has also been observed in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head & neck cancers. Celldex has exclusive rights to EGFRvIII vaccines and is pursuing the development of CDX-110 for GBM therapy, as well as in other cancers through additional clinical studies.

About CDX-1307

CDX-1307 is our lead Antigen Presenting Cell (APC) Targeting Technology product candidate. CDX-1307 is in development for the treatment of colorectal, pancreatic, bladder and breast cancers that express the beta chain of human chorionic gonadotropin, known as Beta hCG, an antigen often found in tumors of these types of cancer. The presence of Beta hCG in these cancers correlates with a poor clinical outcome, suggesting that this molecule may contribute to tumor growth. Normal adult tissues have minimal expression of Beta hCG, therefore, targeted immune responses are not expected to generate significant side effects.

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. is a biotechnology company focused on developing therapeutic vaccines that target and stimulate the body's immune system for the treatment of cancer, infectious and autoimmune diseases. Celldex has three product candidates already in or about to enter clinical development targeting multiple cancers and Hepatitis B. Four additional product candidates are in preclinical development for cancer and autoimmune disease. Celldex's proprietary technology platform uses fully human monoclonal antibodies administered directly to patients to target and stimulate dendritic cells - key cells within the immune system. Celldex was formed in 2004 as a spin-out from Medarex, Inc. The Company is headquartered in Phillipsburg, New Jersey. For more information, please visit the website: .

CONTACT: Robert Burns, Chief Executive Officer, +1-908-454-7120, or ThomasDavis, Chief Medical Officer, +1-908-454-7120, both of CelldexTherapeutics, Inc.; or Dan Budwick of BMC Communications +1-212-477-9007X14

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: May 2007